New drug plus chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called Retlirafusp Alfa combined with standard chemotherapy and radiation for esophageal cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma (a specific type of esophageal cancer).
- Your cancer must be locally advanced (growing into nearby tissues or spread to lymph nodes near the collarbone) and not removable by surgery.
- You must be between 18 and 75 years old.
- You should be in generally good health, able to care for yourself and perform light activities (ECOG 0 or 1).
- You must not have had any previous cancer treatment (such as radiation, chemotherapy, or surgery) for your esophageal cancer.
- Your organs (like liver, kidneys, and bone marrow) must be working well enough, which will be checked with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether special PET/CT scans can help predict how well immunotherapy works before surgery for esophageal cancer. It aims to improve treatment planning by identifying patients who may need additional therapy.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests whether adding an investigational drug called retlirafusp alfa to standard chemotherapy, given before surgery, can improve outcomes for patients with esophageal squamous cell carcinoma. The treatment is given before the tumor is removed, and the trial aims to see if it helps shrink the cancer and improve long-term results.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Hear when a new Esophageal Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.